Chicago, IL, United States of America

Guanglin Li

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Cytoptics Corporation, Kaer Biotherapeutics Corporation. Active years: 2010-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guanglin Li. Retrieved from https://idiyas.com/inventor/guanglin-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 50.0


Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 99(Granted Patents)


Company Filing History:


Years Active: 2010-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Journey of Guanglin Li

Introduction: Guanglin Li, a visionary inventor based in Chicago, IL, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Guanglin Li holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a background in engineering and a passion for problem-solving, Guanglin Li has successfully brought several inventions from concept to reality, revolutionizing industries and improving people's lives.

Collaborations: Throughout his career, Guanglin Li has collaborated with leading research institutions, universities, and tech companies to further develop his inventions and bring them to the market, demonstrating his commitment to innovation and progress.

Conclusion: Guanglin Li's relentless pursuit of innovation and his dedication to creating impactful solutions have solidified his reputation as a pioneering inventor in the vibrant city of Chicago, IL.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…